Retatrutide vs tirzepatide — TRIUMPH-1 vs SURMOUNT-1 head-to-head evidence

This head-to-head sits in Weight Loss Rankings' living editorial database — 200+ research articles and 200+ clinically-verified GLP-1 telehealth providers, sourced only from primary FDA labels, ClinicalTrials.gov registrations, and peer-reviewed PubMed literature.

Retatrutide's pivotal TRIUMPH-1 trial reported roughly −28.3% mean total body weight loss at the 12 mg dose over 80 weeks — about 7.4 percentage points greater than the −20.9% tirzepatide produced at 15 mg over 72 weeks in SURMOUNT-1. But this is an indirect comparison between separate trials, retatrutide carries a harsher GI profile plus a unique dysesthesia signal, and tirzepatide is FDA-approved today while retatrutide remains pre-approval.

The honest short answer

Across the most relevant pivotal datasets:

• Retatrutide produced larger absolute weight loss — about −28.3% mean total body weight loss (TBWL) at the 12 mg dose over 80 weeks in TRIUMPH-1, with a continued −30.3% in the BMI ≥ 35 extension cohort out to 104 weeks (2,339 participants randomized).^[8][9]
• Tirzepatide produced −20.9% mean TBWL at the 15 mg dose over 72 weeks in SURMOUNT-1 (2,539 participants, treatment-regimen estimand).^[4]
• Adverse-event profile is harsher with retatrutide. Nausea ran roughly 42.4% in TRIUMPH-1 versus 14.8% on placebo, compared with about 29% on tirzepatide 15 mg in SURMOUNT-1. Retatrutide also carries a distinct paresthesia/dysesthesia signal (~12.5% vs ~0.9% on placebo) that is not a class feature of tirzepatide.^[1][8]
• Approval status is the decisive practical factor: tirzepatide is FDA-approved as Mounjaro (T2D, 2022) and Zepbound (chronic weight management, 2023), while retatrutide is still pre-filing with the FDA. For most patients in 2026 this is a comparison about what retatrutide could become, not what they can fill at a pharmacy today.

The remainder of this article walks through the mechanism, the head-to-head magnitude numbers, the ≥30% body-weight-loss response rates, the adverse-event differences, the cardiovascular outcomes pipeline, and a decision framework for the moment retatrutide does cross the FDA finish line.

Mechanism: triple agonist vs dual agonist

Tirzepatide is a dual agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 agonism slows gastric emptying, increases satiety, and improves glucose-dependent insulin secretion; GIP agonism appears to layer on additional weight-loss effect plus a partial anti-emetic effect that has shown up across the SURPASS and SURMOUNT programs.^[6][7]

Retatrutide adds a third receptor: glucagon. It is a triple GIP + GLP-1 + glucagon receptor agonist. Glucagon receptor activation increases hepatic energy expenditure, promotes lipolysis, and reduces hepatic steatosis — mechanisms that are essentially unique to this class. The Phase 2 retatrutide trial showed mean weight loss of about 24.2% at 48 weeks (12 mg dose), and the curve had not plateaued by trial end — suggesting the longer 80-week TRIUMPH-1 readout would push higher, which is what happened.^[1][3]

The mechanism asymmetry is also the AE asymmetry. Adding a glucagon-receptor signal to an already-strong incretin backbone amplifies both the weight-loss effect and the unintended consequences — particularly catecholamine-adjacent nervous-system findings like dysesthesia, plus higher peak heart rate in some sub-analyses.

TBWL head-to-head: TRIUMPH-1 vs SURMOUNT-1

Both trials enrolled adults with obesity (or overweight plus comorbidity) and excluded type 2 diabetes. Both used weekly subcutaneous injection plus a structured lifestyle intervention. Both reported on the treatment-regimen estimand — the FDA-preferred ITT analysis that counts all randomized participants regardless of adherence. That makes the magnitude comparison fairly clean, with one critical caveat: they are different trials, run by the same sponsor at different sites, and only a head-to-head randomized trial can rule out residual confounding.

• Retatrutide 12 mg / 80 weeks (TRIUMPH-1): roughly −28.3% mean TBWL on the treatment-regimen estimand. In the BMI ≥ 35 extension cohort, mean TBWL continued to roughly −30.3% at 104 weeks — i.e., still trending down at the two-year mark.^[8][9]
• Tirzepatide 15 mg / 72 weeks (SURMOUNT-1): −20.9% mean TBWL on the treatment-regimen estimand. The lower 5 mg and 10 mg tirzepatide doses produced −15.0% and −19.5% respectively.^[4]

The headline gap: about 7.4 percentage points of absolute TBWL at maximum tested dose, in favor of retatrutide. As a relative number, retatrutide produced roughly 35% more total body weight loss than tirzepatide at trial endpoint. The differential is consistent with what the Phase 2 retatrutide data forecast.^[1]

Indirect-comparison caveat. TRIUMPH-1 and SURMOUNT-1 used different durations (80 vs 72 weeks), different exact lifestyle protocols, slightly different baseline BMI distributions, and different secular contexts (TRIUMPH-1 read out in 2025; SURMOUNT-1 enrolled in 2019–2021). The Lilly-run SURMOUNT-5 head-to-head established that an indirect cross-trial comparison can substantially under-state the head-to-head magnitude in either direction. Until a direct TRIUMPH-vs-SURMOUNT randomized comparison exists, the −28.3% vs −20.9% framing is the best data we have but it is not the same evidence tier as a true head-to-head.

Response rates: who hits ≥20% and ≥30% weight loss

Mean values understate how differently these two drugs distribute their effect. The response-rate tables tell the more clinically useful story.

• ≥20% body weight loss: roughly 83% of retatrutide 12 mg participants reached this threshold in TRIUMPH-1, vs roughly 50% of tirzepatide 15 mg participants in SURMOUNT-1.^[8][4]
• ≥25% body weight loss: roughly 65% of retatrutide 12 mg participants, vs ~32% on tirzepatide 15 mg.^[8][4]
• ≥30% body weight loss: roughly 45% of retatrutide 12 mg participants reached this threshold — historically the territory of bariatric surgery, not pharmacotherapy. Tirzepatide 15 mg produced ≥30% TBWL in a much smaller fraction (single-digit percent range in SURMOUNT-1, depending on estimand).^[8][4]

The ≥30% category is where retatrutide is doing something meaningfully different. Roughly four of every nine participants on the top dose lost more than 30% of their starting body weight — magnitudes typically reserved for sleeve gastrectomy and Roux-en-Y gastric bypass. That is the clinical headline of the TRIUMPH program.

Adverse-event profile head-to-head

Across the two trials, the GI-side-effect ranking at maximum tested dose looks roughly like:

• Nausea: retatrutide 12 mg ~42.4% (vs ~14.8% placebo in TRIUMPH-1) vs tirzepatide 15 mg ~29% in SURMOUNT-1.^[1][4]
• Diarrhea: retatrutide ~27%; tirzepatide ~22%.
• Vomiting: retatrutide ~16%; tirzepatide ~13%.
• Constipation: retatrutide ~14%; tirzepatide ~17%.

The categorically different finding is dysesthesia/paresthesia: roughly 12.5% of retatrutide 12 mg participants reported altered or unpleasant skin sensation (burning, tingling, numbness), vs ~0.9% on placebo. This is not a class effect of GLP-1 or dual GIP/GLP-1 agonism — tirzepatide's SURMOUNT-1 adverse-event table does not flag a comparable signal. The leading mechanistic hypothesis points to glucagon-receptor activity affecting peripheral nerve metabolism or blood flow, though the pathophysiology has not been fully characterized in the retatrutide datasets.^[1][8]

Discontinuation followed the AE pattern. Roughly 11.3% of TRIUMPH-1 retatrutide 12 mg participants discontinued for adverse events, vs about 7.1% on tirzepatide 15 mg in SURMOUNT-1 — both meaningfully higher than the ~3-4% placebo discontinuation rates in either trial. The adverse-event discontinuation differential is consistent with retatrutide producing a stronger pharmacologic effect at the cost of a larger tolerability tax.^[1][4]

Other signals worth tracking from the retatrutide datasets: modest dose-dependent heart-rate increase, mild ALT elevations that resolved on continued treatment, and lipid and metabolite profile changes consistent with substantial hepatic steatosis reduction.^[3]

Approval timeline

Tirzepatide has been FDA-approved as Mounjaro for type 2 diabetes since May 2022 and as Zepbound for chronic weight management since November 2023. Zepbound's indication has since expanded to include moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). For a patient or prescriber in 2026 the drug is available across LillyDirect, retail pharmacies, and the established commercial-insurance prior-authorization pathways.

Retatrutide is pending FDA filing as of mid-2026. Lilly has stated TRIUMPH-1 will support a Biologics License Application; the most-cited expected approval window is 2027, though earliest commercial availability could slip into 2028 depending on FDA review cycles and post-marketing-commitment terms. Until that approval lands, retatrutide is not legally available for prescription outside of ongoing trials (TRIUMPH-3, TRIUMPH-4, TRIUMPH-5).^[2][10]

Compounding pharmacies cannot legally produce retatrutide under the 503A FDCA framework because retatrutide is not on the FDA bulk-substance list and is not a discontinued FDA-approved drug. Any "compounded retatrutide" marketed in 2026 is not produced under FDCA 503A — see our where-to-buy-retatrutide evidence review for the regulatory specifics. The honest practical implication: for any patient deciding between these drugs in 2026, the only legally-available choice is tirzepatide.

Cardiovascular outcomes

Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT, reported topline non-inferiority for major adverse cardiovascular events (MACE) against dulaglutide in type 2 diabetes (2024). The dedicated tirzepatide-obesity CV outcomes trial, SURMOUNT-MMO, is ongoing with results expected in 2027.

Retatrutide's analogous cardiovascular outcomes trial, TRIUMPH-3 (NCT05882045), is enrolling patients with obesity and established cardiovascular disease, with an estimated primary completion in 2027. Until those data read out, the cardiovascular benefit assumption for retatrutide is circumstantial — it produces larger weight loss, blood pressure reduction, and lipid/metabolic improvement than tirzepatide on cross-trial comparison, so the mechanistic case for cardiovascular benefit is strong, but the formal evidence base is currently zero.^[3][10]

Which one to choose

For the realistic moment most patients face today — only tirzepatide is FDA-approved — the comparison resolves to "tirzepatide, until retatrutide reaches the market." For the moment retatrutide does get FDA approval, here is a framework based on the comparative evidence above.

• BMI ≥ 40 + need for ≥25% weight loss to clear surgical-eligibility thresholds or comorbidity targets: retatrutide is the leading candidate. The ≥30% TBWL response rate near 45% is the closest pharmacotherapy has come to bariatric-surgery-range outcomes.
• BMI 30–35 seeking 15–20% TBWL: tirzepatide. The marginal benefit of retatrutide's stronger effect doesn't obviously outweigh the tolerability cost, and tirzepatide has a longer post-marketing safety record by the time retatrutide is available.
• History of GI sensitivity or prior GLP-1 intolerance: tirzepatide, by a clear margin. Retatrutide's nausea, vomiting, and discontinuation rates are categorically higher.
• Peripheral neuropathy history or active paresthesia symptoms: tirzepatide. The 12.5% retatrutide dysesthesia signal is the cleanest contraindication in the comparative dataset.
• Established cardiovascular disease: tirzepatide until SURMOUNT-MMO reads out; potentially retatrutide post-TRIUMPH-3. Both will require formal CV outcomes data before guidelines push them as cardiovascular-protective.
• Type 2 diabetes: tirzepatide. It is already FDA-approved as Mounjaro for T2D with SURPASS program backing; retatrutide's glycemic data are promising but its T2D program is earlier-stage.^[6][7]

Related research

• Triple agonist evidence base: Retatrutide as a triple GIP/GLP-1/glucagon agonist — evidence review — the mechanism deep-dive behind why a third receptor changes the magnitude ceiling.
• TRIUMPH-1 pivotal: Retatrutide TRIUMPH-1 phase 3 results — full evidence review — the standalone pivotal-trial readout this comparison draws on.
• Approval and access: Retatrutide FDA approval and access timeline — current filing status, expected commercial launch window, and the 503A compounding analysis.
• Adverse-event deep dive: Retatrutide side effects — comprehensive evidence review — including the dysesthesia signal and the dose-titration data that shape real-world tolerability.
• The other head-to-head: Tirzepatide vs semaglutide — SURMOUNT-5 head-to-head evidence — the currently-approved-drug comparison most patients actually face in 2026.
• Full medication taxonomy: GLP-1 medication list — full FDA reference — every FDA-approved GLP-1, GIP/GLP-1, and pipeline triple agonist with indication, dose, and trial provenance.